Evidence map›Paper›PMID 39251683›Full record

ArticleNPJ precision oncology2024

A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation.

Subotheni Thavaneswaran, Frank Lin, John P Grady, David Espinoza, Min Li Huang, Sarah Chinchen, Lucille Sebastian, Maya Kansara, Tony Mersiades, Chee Khoon Lee and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Subotheni ThavaneswaranNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia. s.thavaneswaran@garvan.org.au.ORCID http://orcid.org/0000-0002-8946-6709
Frank LinNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0001-9250-6874
John P GradyGarvan Institute of Medical Research, Sydney, NSW, Australia.
David EspinozaNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Min Li HuangSchool of Clinical Medicine, Faculty of Medicine and Health, University of NSW, Sydney, NSW, Australia.
Sarah ChinchenNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Lucille SebastianNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Maya KansaraGarvan Institute of Medical Research, Sydney, NSW, Australia.
Tony MersiadesNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Chee Khoon LeeNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Jayesh DesaiPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0003-4246-9344
Peter GrimisonChris O'Brien Lifehouse, Sydney, NSW, Australia.
Michael BrownRoyal Adelaide Hospital, Adelaide, SA, Australia.
Michael MillwardLinear Clinical Research & University of Western Australia, Perth, WA, Australia.
Rosemary HarrupRoyal Hobart Hospital, Hobart, TAS, Australia.
Ken O'ByrnePrincess Alexandra Hospital and Queensland University of Technology, Brisbane, QLD, Australia.
Adnan NagrialWestmead Hospital, Sydney, NSW, Australia.
Paul CraftThe Canberra Hospital, Canberra, ACT, Australia.
John SimesNHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.ORCID http://orcid.org/0000-0002-3740-7563
Anthony M JoshuaThe Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia.
David M ThomasThe Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This single-arm phase II non-randomised trial (ACTRN12619001265167) evaluated trastuzumab emtansine in solid cancers with HER2 amplification or mutation detected by comprehensive genomic profiling. The primary objective was objective response (OR), while secondary objectives included the time to progression (TTP) on study to TTP on prior therapy ratio, progression-free survival (PFS) and overall survival (OS). The cohort included 16 tumours with HER2 mutations (group 1) and 16 with HER2 amplification (group 2). After 17 months median follow-up, ORs occurred in 19% of group 1 (1 salivary gland carcinoma (SGC), 2 lung cancers) and 25% of group 2 (3 SGCs, 1 uterine carcinoma). Fourteen of 29 TTP-evaluable patients achieved a TTP ratio ≥1.3, including 10 without an OR. Median PFS and OS were 4.5 (95% CI 2.1-7.0) and 18.2 months (95% CI 8.1-not reached) respectively. Trastuzumab emtansine showed modest ORs and a favourable change in disease trajectory in select HER2-altered solid cancers.

Identifiers

PMID39251683
PMCPMC11385980

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.